Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy

Key points: Clinically significant bleeding occurred in 9% of patients after CAR T therapy and was associated with features of systemic coagulopathy. Low baseline platelets and possibly high-grade ICANS are risk factors for bleeding and require close monitoring for bleeding up to 1 month.